(DMP) Dermapharm Holding SE - Ratings and Ratios
Generics, Biosimilars, Therapeutics, Dermatology
DMP EPS (Earnings per Share)
DMP Revenue
Description: DMP Dermapharm Holding SE
Dermapharm Holding SE is a German pharmaceutical company with a market capitalization of approximately €1.945 billion. As a player in the pharmaceuticals industry, the companys performance is influenced by factors such as R&D pipeline, regulatory approvals, and competition.
The stock has experienced a decline in recent times, with the current price at €32.25, down from its 52-week high of €41.20. This volatility is reflected in its beta of 1.276, indicating that the stock is more sensitive to market fluctuations than the overall market.
From a fundamental analysis perspective, Dermapharms price-to-earnings ratio stands at 18.39, which is relatively moderate. The forward P/E ratio of 14.12 suggests that the market expects earnings to grow in the future. Additionally, the companys return on equity (RoE) is 17.42%, indicating a decent level of profitability.
To further assess the companys performance, key drivers such as revenue growth, gross margin, and operating expenses should be monitored. A high gross margin would indicate the companys ability to maintain pricing power, while a stable or decreasing operating expense ratio would suggest efficient cost management. Other relevant KPIs include the companys debt-to-equity ratio and interest coverage ratio, which can provide insights into its capital structure and ability to meet its financial obligations.
The pharmaceutical industry is subject to various economic drivers, including government regulations, patent expirations, and demographic changes. Dermapharms success will depend on its ability to navigate these factors, invest in R&D, and expand its product portfolio. A thorough analysis of the companys financials and industry trends is necessary to make informed investment decisions.
DMP Stock Overview
| Market Cap in USD | 2,080m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
DMP Stock Ratings
| Growth Rating | -22.0% |
| Fundamental | 72.8% |
| Dividend Rating | 46.2% |
| Return 12m vs S&P 500 | -20.5% |
| Analyst Rating | - |
DMP Dividends
| Dividend Yield 12m | 2.66% |
| Yield on Cost 5y | 2.36% |
| Annual Growth 5y | 17.08% |
| Payout Consistency | 92.3% |
| Payout Ratio | 51.4% |
DMP Growth Ratios
| Growth Correlation 3m | -55.8% |
| Growth Correlation 12m | -5.2% |
| Growth Correlation 5y | -74% |
| CAGR 5y | -2.59% |
| CAGR/Max DD 3y | -0.07 |
| CAGR/Mean DD 3y | -0.14 |
| Sharpe Ratio 12m | -0.15 |
| Alpha | 0.22 |
| Beta | 0.000 |
| Volatility | 27.98% |
| Current Volume | 9.5k |
| Average Volume 20d | 15.9k |
| Stop Loss | 31.6 (-3.1%) |
| Signal | -0.40 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (107.2m TTM) > 0 and > 6% of Revenue (6% = 70.6m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 2.93pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 25.69% (prev 22.58%; Δ 3.11pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 215.5m > Net Income 107.2m (YES >=105%, WARN >=100%) |
| Net Debt (846.9m) to EBITDA (306.3m) ratio: 2.76 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (53.6m) change vs 12m ago -0.72% (target <= -2.0% for YES) |
| Gross Margin 65.67% (prev 38.78%; Δ 26.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 54.20% (prev 51.28%; Δ 2.92pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.63 (EBITDA TTM 306.3m / Interest Expense TTM 60.5m) >= 6 (WARN >= 3) |
Altman Z'' 2.61
| (A) 0.14 = (Total Current Assets 662.6m - Total Current Liabilities 360.3m) / Total Assets 2.14b |
| (B) 0.21 = Retained Earnings (Balance) 437.8m / Total Assets 2.14b |
| (C) 0.10 = EBIT TTM 219.4m / Avg Total Assets 2.17b |
| (D) 0.32 = Book Value of Equity 491.6m / Total Liabilities 1.53b |
| Total Rating: 2.61 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 72.75
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 6.73% = 3.37 |
| 3. FCF Margin 14.90% = 3.73 |
| 4. Debt/Equity 1.64 = 1.29 |
| 5. Debt/Ebitda 3.25 = -2.08 |
| 6. ROIC - WACC (= 8.83)% = 11.04 |
| 7. RoE 17.61% = 1.47 |
| 8. Rev. Trend 19.21% = 1.44 |
| 9. EPS Trend -10.06% = -0.50 |
What is the price of DMP shares?
Over the past week, the price has changed by -0.91%, over one month by -3.41%, over three months by -6.26% and over the past year by -5.59%.
Is Dermapharm Holding SE a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DMP is around 30.80 EUR . This means that DMP is currently overvalued and has a potential downside of -5.52%.
Is DMP a buy, sell or hold?
What are the forecasts/targets for the DMP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 47 | 44.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 33.1 | 1.6% |
DMP Fundamental Data Overview
Market Cap EUR = 1.77b (1.77b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 165.9m EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 16.5578
P/E Forward = 16.4474
P/S = 1.4896
P/B = 2.8989
Beta = 1.272
Revenue TTM = 1.18b EUR
EBIT TTM = 219.4m EUR
EBITDA TTM = 306.3m EUR
Long Term Debt = 910.9m EUR (from longTermDebt, last quarter)
Short Term Debt = 84.6m EUR (from shortTermDebt, last quarter)
Debt = 995.5m EUR (Calculated: Short Term 84.6m + Long Term 910.9m)
Net Debt = 846.9m EUR (from netDebt column, last quarter)
Enterprise Value = 2.60b EUR (1.77b + Debt 995.5m - CCE 165.9m)
Interest Coverage Ratio = 3.63 (Ebit TTM 219.4m / Interest Expense TTM 60.5m)
FCF Yield = 6.73% (FCF TTM 175.3m / Enterprise Value 2.60b)
FCF Margin = 14.90% (FCF TTM 175.3m / Revenue TTM 1.18b)
Net Margin = 9.11% (Net Income TTM 107.2m / Revenue TTM 1.18b)
Gross Margin = 65.67% ((Revenue TTM 1.18b - Cost of Revenue TTM 403.9m) / Revenue TTM)
Tobins Q-Ratio = 5.30 (Enterprise Value 2.60b / Book Value Of Equity 491.6m)
Interest Expense / Debt = 1.32% (Interest Expense 13.2m / Debt 995.5m)
Taxrate = 35.04% (60.3m / 172.0m)
NOPAT = 142.5m (EBIT 219.4m * (1 - 35.04%))
Current Ratio = 1.84 (Total Current Assets 662.6m / Total Current Liabilities 360.3m)
Debt / Equity = 1.64 (Debt 995.5m / last Quarter total Stockholder Equity 608.2m)
Debt / EBITDA = 3.25 (Net Debt 846.9m / EBITDA 306.3m)
Debt / FCF = 5.68 (Debt 995.5m / FCF TTM 175.3m)
Total Stockholder Equity = 608.7m (last 4 quarters mean)
RoA = 5.02% (Net Income 107.2m, Total Assets 2.14b )
RoE = 17.61% (Net Income TTM 107.2m / Total Stockholder Equity 608.7m)
RoCE = 14.44% (Ebit 219.4m / (Equity 608.7m + L.T.Debt 910.9m))
RoIC = 13.00% (NOPAT 142.5m / Invested Capital 1.10b)
WACC = 4.17% (E(1.77b)/V(2.77b) * Re(6.02%)) + (D(995.5m)/V(2.77b) * Rd(1.32%) * (1-Tc(0.35)))
Shares Correlation 3-Years: 9.87 | Cagr: -0.03%
Discount Rate = 6.02% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 79.30% ; FCFE base≈151.8m ; Y1≈163.2m ; Y5≈199.8m
Fair Price DCF = 64.82 (DCF Value 3.49b / Shares Outstanding 53.8m; 5y FCF grow 8.36% → 3.0% )
EPS Correlation: -10.06 | EPS CAGR: -13.04% | SUE: 0.00 | # QB: 0
Revenue Correlation: 19.21 | Revenue CAGR: 1.23% | SUE: N/A | # QB: None